3 completed, 1 terminated. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Terminated 1 |
Follow Antimitotic Agents: new trials by email Literature Review of Antimitotic Agents trials Research Report on Antimitotic Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer AZD1775, AZD1775 Placebo, Antimitotic Agent - Previously Treated Non Small Cell Lung Cancer | Phase 2 | Terminated | AstraZeneca | 48 | 2014-03-01 | 2016-06-14 |
| A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer MEK162, MEK inhibitor; oral, Paclitaxel, mitotic inhibitor; intravenous - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Completed | Array Biopharma, now a wholly owned subsidiary of Pfizer | 36 | 2012-07-01 | 2020-09-14 |
| A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer BIIB022 With Paclitaxel and Carboplatin - Non-Small Cell Lung Cancer | Phase 1 | Completed | Biogen | 18 | 2009-10-01 | 2013-09-16 |
| A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer ARRY-334543, EGFR/ErbB2 inhibitor; oral, Docetaxel, mitotic inhibitor; intravenous, Prophylactic growth factors; subcutaneous - Advanced Cancer | Phase 1 | Completed | Array Biopharma, now a wholly owned subsidiary of Pfizer | 27 | 2009-01-01 | 2020-10-06 |
Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Fallopian Tube Neoplasms (1)
Array Biopharma, now a wholly owned subsidiary of Pfizer (2) · AstraZeneca (1) · Biogen (1)
United States (4)